

Outlook Therapeutics, Inc. Logo

Oncobiologics, Inc. to Present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conference

July 6, 2016

CRANBURY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and President, Pankaj Mohan, Ph.D., will present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conference at 9 a.m. EDT, July 13, 2016 at Le Parker Meridien, New York City.

Investors may access live and archived versions of the webcast of this presentation on the investor relations page of the company's website at <http://ir.oncobiologics.com>.

About Oncobiologics, Inc. and its BioSymphony™ Platform

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Its current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. Oncobiologics is advancing its pipeline of eight biosimilar products, two of which are currently in clinical development. Led by a team of biopharmaceutical experts, Oncobiologics operates from in-house state-of-the-art fully integrated research and development, and manufacturing facility in Cranbury, New Jersey. Oncobiologics employs its BioSymphony™ Platform to address the challenges of biosimilar development and commercialization by developing high quality mAb biosimilars in an efficient and cost-effective manner on an accelerated timeline. For more information, please visit www.oncobiologics.com.

Oncobiologics:

Lawrence A. Kenyon

Chief Financial Officer

LawrenceKenyon@oncobiologics.com

Investors and Media:

Alex Fudukidis

Russo Partners, LLC

alex.fudukidis@russopartnersllc.com



Oncobiologics, Inc.